The Centre has issued a detailed advisory on GLP-1 receptor agonist drugs, emphasizing their use for type 2 diabetes and obesity must be strictly under medical supervision. Authorities are increasing regulatory surveillance and warning of strict action against violations in their sale or prescription.

from India News | Latest India News Today & Real-time News from India, India Breaking News https://ift.tt/PUHaD1K